A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer (Q33367733)

26 July 2017

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer (English)

1 reference

26 July 2017

phase III clinical trial

0 references

1 reference

M Peeters

5

0 references

author name string

H Oettle

1

1 reference

26 July 2017

D Richards

2

1 reference

26 July 2017

R K Ramanathan

3

1 reference

26 July 2017

J L van Laethem

4

1 reference

26 July 2017

M Fuchs

6

1 reference

26 July 2017

A Zimmermann

7

1 reference

26 July 2017

W John

8

1 reference

26 July 2017

D Von Hoff

9

1 reference

26 July 2017

M Arning

10

1 reference

26 July 2017

H L Kindler

11

1 reference

26 July 2017

language of work or name

1 reference

8 August 2005

1 reference

26 July 2017

1 reference

26 July 2017

16

1 reference

26 July 2017

10

1 reference

26 July 2017

1639-1645

1 reference

Estimating the world cancer burden: Globocan 2000.

26 July 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI309

Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI309

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI309

Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI309

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI309

Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI309

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI309

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI309

Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI309

The pemetrexed/gemcitabine combination in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI309

A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI309

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI309

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI309

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI309

Missing quality of life data in cancer clinical trials: serious problems and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI309

A new look at the statistical model identification

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI309

Advanced pancreatic cancer--5 years on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI309

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI309

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI309

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDI309

1 reference

26 July 2017

1 reference